{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:19:32Z","timestamp":1762431572840,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T00:00:00Z","timestamp":1548374400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s12020-019-01846-8","type":"journal-article","created":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T10:48:17Z","timestamp":1548413297000},"page":"322-329","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["68Ga-DOTANOC and 18F-FDG PET\/CT in metastatic medullary thyroid carcinoma: novel correlations with tumoral biomarkers"],"prefix":"10.1007","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1359-814X","authenticated-orcid":false,"given":"Pedro","family":"Souteiro","sequence":"first","affiliation":[]},{"given":"Patr\u00edcia","family":"Gouveia","sequence":"additional","affiliation":[]},{"given":"Gon\u00e7alo","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"Sandra","family":"Belo","sequence":"additional","affiliation":[]},{"given":"Cl\u00e1udia","family":"Costa","sequence":"additional","affiliation":[]},{"given":"Davide","family":"Carvalho","sequence":"additional","affiliation":[]},{"given":"Hugo","family":"Duarte","sequence":"additional","affiliation":[]},{"given":"In\u00eas Lucena","family":"Sampaio","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,1,25]]},"reference":[{"key":"1846_CR1","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","volume":"25","author":"SA Wells Jr.","year":"2015","unstructured":"S.A. Wells Jr., S.L. Asa, H. Dralle, R. Elisei, D.B. Evans, R.F. Gagel et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25, 567\u2013610 (2015)","journal-title":"Thyroid"},{"key":"1846_CR2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.clon.2010.05.002","volume":"22","author":"F Pacini","year":"2010","unstructured":"F. Pacini, M.G. Castagna, C. Cipri, M. Schlumberger, Medullary thyroid carcinoma. Clin. Oncol. (R. Coll. Radiol.) 22, 475\u2013485 (2010)","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"key":"1846_CR3","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1089\/thy.2018.0067","volume":"28","author":"J Schmidt Jensen","year":"2018","unstructured":"J. Schmidt Jensen, C. Gronhoj, C. Mirian, D.H. Jensen, J. Friborg, C.H. Hahn et al. Incidence and survival of thyroid cancer in children, adolescents, and young adults in Denmark: A Nationwide Study from 1980 to 2014. Thyroid 28, 1128\u20131133 (2018)","journal-title":"Thyroid"},{"key":"1846_CR4","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00268-017-4321-z","volume":"42","author":"F Torresan","year":"2018","unstructured":"F. Torresan, E. Cavedon, C. Mian, M. Iacobone, Long-term outcome after surgery for medullary thyroid carcinoma: A single-center experience. World J. Surg. 42, 367\u2013375 (2018)","journal-title":"World J. Surg."},{"key":"1846_CR5","first-page":"289","volume":"142","author":"A Machens","year":"2007","unstructured":"A. Machens, J. Ukkat, S. Hauptmann, H. Dralle, Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis. Arch. Surg. (Chic., Ill: 1960) 142, 289\u2013293 (2007). (discussion 294)","journal-title":"Arch. Surg. (Chic., Ill: 1960)"},{"key":"1846_CR6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1530\/EJE-14-0076","volume":"171","author":"K Saltiki","year":"2014","unstructured":"K. Saltiki, G. Rentziou, K. Stamatelopoulos, G. Georgiopoulos, C. Stavrianos, E. Lambrinoudaki et al. Small medullary thyroid carcinoma: post-operative calcitonin rather than tumour size predicts disease persistence and progression. Eur. J. Endocrinol. 171, 117\u2013126 (2014)","journal-title":"Eur. J. Endocrinol."},{"key":"1846_CR7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1530\/EJE-07-0667","volume":"158","author":"A Laure Giraudet","year":"2008","unstructured":"A. Laure Giraudet, A. Al Ghulzan, A. Auperin, S. Leboulleux, A. Chehboun, F. Troalen et al. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur. J. Endocrinol. 158, 239\u2013246 (2008)","journal-title":"Eur. J. Endocrinol."},{"key":"1846_CR8","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1007\/s00259-017-3728-y","volume":"44","author":"MF Bozkurt","year":"2017","unstructured":"M.F. Bozkurt, I. Virgolini, S. Balogova, M. Beheshti, D. Rubello, C. Decristoforo et al. Guideline for PET\/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. Eur. J. Nucl. Med. Mol. Imaging 44, 1588\u20131601 (2017)","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1846_CR9","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00259-011-2031-6","volume":"39","author":"G Treglia","year":"2012","unstructured":"G. Treglia, P. Castaldi, M.F. Villani, G. Perotti, C. de Waure, A. Filice et al. Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET\/CT in patients with recurrent medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 39, 569\u2013580 (2012)","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1846_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00259-009-1204-z","volume":"37","author":"BG Conry","year":"2010","unstructured":"B.G. Conry, N.D. Papathanasiou, V. Prakash, I. Kayani, M. Caplin, S. Mahmood et al. Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET\/CT in the detection of recurrent medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 37, 49\u201357 (2010)","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1846_CR11","first-page":"2417","volume":"83","author":"E Mato","year":"1998","unstructured":"E. Mato, X. Matias-Guiu, A. Chico, S.M. Webb, R. Cabezas, L. Berna et al. Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 83, 2417\u20132420 (1998)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1846_CR12","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.diii.2013.07.006","volume":"95","author":"MO Oksuz","year":"2014","unstructured":"M.O. Oksuz, L. Winter, C. Pfannenberg, G. Reischl, K. Mussig, R. Bares et al. Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC? Diagn. Interv. Imaging 95, 289\u2013300 (2014)","journal-title":"Diagn. Interv. Imaging"},{"key":"1846_CR13","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.7150\/thno.19588","volume":"7","author":"E Hindi\u00e9","year":"2017","unstructured":"E. Hindi\u00e9, The NETPET Score: Combining FDG and somatostatin receptor imaging for optimal management of patients with metastatic well-differentiated neuroendocrine tumors. Theranostics 7, 1159\u20131163 (2017)","journal-title":"Theranostics"},{"key":"1846_CR14","first-page":"324686","volume":"2012","author":"G Treglia","year":"2012","unstructured":"G. Treglia, V. Rufini, M. Salvatori, A. Giordano, L. Giovanella, PET imaging in Recurrent Medullary Thyroid Carcinoma. Int. J. Mol. Imaging 2012, 324686 (2012)","journal-title":"Int. J. Mol. Imaging"},{"key":"1846_CR15","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/00000658-198404000-00014","volume":"199","author":"A Miyauchi","year":"1984","unstructured":"A. Miyauchi, T. Onishi, S. Morimoto, S. Takai, F. Matsuzuka, K. Kuma et al. Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma. Ann. Surg. 199, 461\u2013466 (1984)","journal-title":"Ann. Surg."},{"key":"1846_CR16","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1089\/thy.2017.0102","volume":"27","author":"RM Tuttle","year":"2017","unstructured":"R.M. Tuttle, B. Haugen, N.D. Perrier, Updated American Joint Committee on cancer\/tumor-node-metastasis staging system for differentiated and anaplasticthyroid cancer (eighth edition): What changed and why? Thyroid 27, 751\u2013756 (2017)","journal-title":"Thyroid"},{"key":"1846_CR17","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1097\/MNM.0b013e3283541157","volume":"33","author":"N Naswa","year":"2012","unstructured":"N. Naswa, P. Sharma, S. Suman Kc, S. Lata, R. Kumar, A. Malhotra et al. Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Nucl. Med. Commun. 33, 766\u2013774 (2012)","journal-title":"Nucl. Med. Commun."},{"key":"1846_CR18","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/MNM.0000000000000240","volume":"36","author":"ZG Ozkan","year":"2015","unstructured":"Z.G. Ozkan, S. Kuyumcu, A.K. Uzum, M.F. Gecer, S. Ozel, F. Aral et al. Comparison of (6)(8)Ga-DOTATATE PET-CT, (1)(8)F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma. Nucl. Med. Commun. 36, 242\u2013250 (2015)","journal-title":"Nucl. Med. Commun."},{"key":"1846_CR19","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/j.rpor.2014.04.016","volume":"19","author":"K Kilian","year":"2014","unstructured":"K. Kilian, (68)Ga-DOTA and analogs: Current status and future perspectives. Rep. Pract. Oncol. Radiother. 19, S13\u2013S21 (2014)","journal-title":"Rep. Pract. Oncol. Radiother."},{"key":"1846_CR20","first-page":"426","volume":"4","author":"A Mojtahedi","year":"2014","unstructured":"A. Mojtahedi, S. Thamake, I. Tworowska, D. Ranganathan, E.S. Delpassand, The value of (68)Ga-DOTATATE PET\/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature. Am. J. Nucl. Med. Mol. Imaging 4, 426\u2013434 (2014)","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"1846_CR21","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1046\/j.1365-2265.2001.01175.x","volume":"54","author":"M Papotti","year":"2001","unstructured":"M. Papotti, U. Kumar, M. Volante, C. Pecchioni, Y.C. Patel, Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. Clin. Endocrinol. (Oxf.). 54, 641\u2013649 (2001)","journal-title":"Clin. Endocrinol. (Oxf.)."},{"key":"1846_CR22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/RLU.0000000000000628","volume":"40","author":"F Vaisman","year":"2015","unstructured":"F. Vaisman, P.H. Rosado de Castro, F.P. Lopes, D.B. Kendler, C.H. Pessoa, D.A. Bulzico et al. Is there a role for peptide receptor radionuclide therapy in medullary thyroid cancer? Clin. Nucl. Med. 40, 123\u2013127 (2015)","journal-title":"Clin. Nucl. Med."},{"key":"1846_CR23","doi-asserted-by":"publisher","first-page":"6696","DOI":"10.1158\/1078-0432.CCR-07-0935","volume":"13","author":"F Iten","year":"2007","unstructured":"F. Iten, B. Muller, C. Schindler, C. Rochlitz, D. Oertli, H.R. Macke et al. Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin. Cancer Res. 13, 6696\u20136702 (2007)","journal-title":"Clin. Cancer Res."},{"key":"1846_CR24","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1007\/s00259-016-3328-2","volume":"43","author":"B Nilica","year":"2016","unstructured":"B. Nilica, D. Waitz, V. Stevanovic, C. Uprimny, D. Kendler, S. Buxbaum et al. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET\/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle. Eur. J. Nucl. Med. Mol. Imaging 43, 1585\u20131592 (2016)","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1846_CR25","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/j.1365-2265.2009.03666.x","volume":"72","author":"JA Meijer","year":"2010","unstructured":"J.A. Meijer, S. le Cessie, W.B. van den Hout, J. Kievit, J.W. Schoones, J.A. Romijn et al. Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis. Clin. Endocrinol. (Oxf.). 72, 534\u2013542 (2010)","journal-title":"Clin. Endocrinol. (Oxf.)."},{"key":"1846_CR26","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.2967\/jnumed.112.105940","volume":"53","author":"HH Verbeek","year":"2012","unstructured":"H.H. Verbeek, J.T. Plukker, K.P. Koopmans, J.W. de Groot, R.M. Hofstra, A.C. Muller Kobold et al. Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma. J. Nucl. Med. 53, 1863\u20131871 (2012)","journal-title":"J. Nucl. Med."},{"key":"1846_CR27","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s11307-009-0276-2","volume":"12","author":"TV Bogsrud","year":"2010","unstructured":"T.V. Bogsrud, D. Karantanis, M.A. Nathan, B.P. Mullan, G.A. Wiseman, J.L. Kasperbauer et al. The prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in patients with suspected residual or recurrent medullary thyroid carcinoma. Mol. Imaging Biol.: MIB 12, 547\u2013553 (2010)","journal-title":"Mol. Imaging Biol.: MIB"},{"key":"1846_CR28","doi-asserted-by":"publisher","first-page":"4185","DOI":"10.1210\/jc.2007-1211","volume":"92","author":"AL Giraudet","year":"2007","unstructured":"A.L. Giraudet, D. Vanel, S. Leboulleux, A. Auperin, C. Dromain, L. Chami et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J. Clin. Endocrinol. Metab. 92, 4185\u20134190 (2007)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1846_CR29","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1007\/s00259-017-3701-9","volume":"44","author":"LYI Yamaga","year":"2017","unstructured":"L.Y.I. Yamaga, M.L. Cunha, G.C. Campos Neto, M.R.T. Garcia, J.H. Yang, C.P. Camacho et al. 68Ga-DOTATATE PET\/CT in recurrent medullary thyroid carcinoma: a lesion-by-lesion comparison with (111)In-octreotide SPECT\/CT and conventional imaging. Eur. J. Nucl. Med. Mol. Imaging 44, 1695\u20131701 (2017)","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1846_CR30","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1007\/s00259-017-3759-4","volume":"44","author":"AR Romero-Lluch","year":"2017","unstructured":"A.R. Romero-Lluch, J.I. Cuenca-Cuenca, R. Guerrero-Vazquez, A.J. Martinez-Ortega, J.L. Tirado-Hospital, I. Borrego-Dorado et al. Diagnostic utility of PET\/CT with (18)F-DOPA and (18)F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff. Eur. J. Nucl. Med. Mol. Imaging 44, 2004\u20132013 (2017)","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-019-01846-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-019-01846-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-019-01846-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T19:30:55Z","timestamp":1579894255000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-019-01846-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,25]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["1846"],"URL":"https:\/\/doi.org\/10.1007\/s12020-019-01846-8","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"type":"print","value":"1355-008X"},{"type":"electronic","value":"1559-0100"}],"subject":[],"published":{"date-parts":[[2019,1,25]]},"assertion":[{"value":"12 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All patients gave their consent to be enroled in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}